Cargando…

Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran

BACKGROUND: Breast cancer is the second leading cause of death due to cancer in women. Triple negative breast cancer (TNBC) is a subgroup with unique behavior. There is a controversy in organ involvement in metastasis. In this study, we planned to define the prognostic factors, survival, and recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mousavi, Seied Asadollah, Kasaeian, Amir, Pourkasmaee, Maziar, Ghavamzadeh, Ardeshir, Alimoghaddam, Kamran, Vaezi, Mohammad, Kamranzadeh Fumani, Hosein, Babakhani, Davoud, Tavakoli, Sahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319722/
https://www.ncbi.nlm.nih.gov/pubmed/30608935
http://dx.doi.org/10.1371/journal.pone.0208701
_version_ 1783385113925517312
author Mousavi, Seied Asadollah
Kasaeian, Amir
Pourkasmaee, Maziar
Ghavamzadeh, Ardeshir
Alimoghaddam, Kamran
Vaezi, Mohammad
Kamranzadeh Fumani, Hosein
Babakhani, Davoud
Tavakoli, Sahar
author_facet Mousavi, Seied Asadollah
Kasaeian, Amir
Pourkasmaee, Maziar
Ghavamzadeh, Ardeshir
Alimoghaddam, Kamran
Vaezi, Mohammad
Kamranzadeh Fumani, Hosein
Babakhani, Davoud
Tavakoli, Sahar
author_sort Mousavi, Seied Asadollah
collection PubMed
description BACKGROUND: Breast cancer is the second leading cause of death due to cancer in women. Triple negative breast cancer (TNBC) is a subgroup with unique behavior. There is a controversy in organ involvement in metastasis. In this study, we planned to define the prognostic factors, survival, and recurrence incidence of patients. MATERIALS AND METHOD: Among the 583 patients with breast mass referred to hematology and oncology clinic in Shariati hospital, Tehran, Iran from March 2005 to March 2015, fifty four patients entered the survival analysis whom we followed for two years until March 2017. Overall survival (OS) and disease-free survival (DFS) and Cumulative recurrence incidences (RI) were estimated. Univariate and multivariate Cox proportional hazards regression was performed to assess risk factors in predicting OS and DFS. RESULTS: Median follow up for the patients was 5.00 years. The five-year OS, DFS and RI were 86.13% (95% CI (71.42–93.59), 63.09% (95% CI (47.04–75.49) and 32.15% (95% CI (19.52–47.43) respectively. Among the factors studied OS, DFS and RI differed significantly only between patients with and without nodal involvement (P = 0.004, P = 0.003, and P = 0.02 respectively). On the other hand, based on the univariate modeling, patients with nodal involvement had a higher risk of breast cancer-specific death (HR: 17.99, P = 0.004). Furthermore, patients with nodal involvement had a higher risk of breast cancer-specific death or recurrence (HR = 5.64, P = 0.008). In Multivariate model, just the nodal involvement significantly changed the hazard for OS (HR = 23.91, P = 0.001). As the nodal involvement was the only significant risk factor at the 0.2 level of significance, we can consider the hazard ratio of lymph node positivity in DFS univariate models as adjusted hazard. CONCLUSION: The only factor with significant effect on OS, DFS and RI was nodal involvement in the pathology report.
format Online
Article
Text
id pubmed-6319722
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63197222019-01-19 Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran Mousavi, Seied Asadollah Kasaeian, Amir Pourkasmaee, Maziar Ghavamzadeh, Ardeshir Alimoghaddam, Kamran Vaezi, Mohammad Kamranzadeh Fumani, Hosein Babakhani, Davoud Tavakoli, Sahar PLoS One Research Article BACKGROUND: Breast cancer is the second leading cause of death due to cancer in women. Triple negative breast cancer (TNBC) is a subgroup with unique behavior. There is a controversy in organ involvement in metastasis. In this study, we planned to define the prognostic factors, survival, and recurrence incidence of patients. MATERIALS AND METHOD: Among the 583 patients with breast mass referred to hematology and oncology clinic in Shariati hospital, Tehran, Iran from March 2005 to March 2015, fifty four patients entered the survival analysis whom we followed for two years until March 2017. Overall survival (OS) and disease-free survival (DFS) and Cumulative recurrence incidences (RI) were estimated. Univariate and multivariate Cox proportional hazards regression was performed to assess risk factors in predicting OS and DFS. RESULTS: Median follow up for the patients was 5.00 years. The five-year OS, DFS and RI were 86.13% (95% CI (71.42–93.59), 63.09% (95% CI (47.04–75.49) and 32.15% (95% CI (19.52–47.43) respectively. Among the factors studied OS, DFS and RI differed significantly only between patients with and without nodal involvement (P = 0.004, P = 0.003, and P = 0.02 respectively). On the other hand, based on the univariate modeling, patients with nodal involvement had a higher risk of breast cancer-specific death (HR: 17.99, P = 0.004). Furthermore, patients with nodal involvement had a higher risk of breast cancer-specific death or recurrence (HR = 5.64, P = 0.008). In Multivariate model, just the nodal involvement significantly changed the hazard for OS (HR = 23.91, P = 0.001). As the nodal involvement was the only significant risk factor at the 0.2 level of significance, we can consider the hazard ratio of lymph node positivity in DFS univariate models as adjusted hazard. CONCLUSION: The only factor with significant effect on OS, DFS and RI was nodal involvement in the pathology report. Public Library of Science 2019-01-04 /pmc/articles/PMC6319722/ /pubmed/30608935 http://dx.doi.org/10.1371/journal.pone.0208701 Text en © 2019 Mousavi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mousavi, Seied Asadollah
Kasaeian, Amir
Pourkasmaee, Maziar
Ghavamzadeh, Ardeshir
Alimoghaddam, Kamran
Vaezi, Mohammad
Kamranzadeh Fumani, Hosein
Babakhani, Davoud
Tavakoli, Sahar
Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran
title Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran
title_full Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran
title_fullStr Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran
title_full_unstemmed Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran
title_short Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran
title_sort assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319722/
https://www.ncbi.nlm.nih.gov/pubmed/30608935
http://dx.doi.org/10.1371/journal.pone.0208701
work_keys_str_mv AT mousaviseiedasadollah assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT kasaeianamir assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT pourkasmaeemaziar assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT ghavamzadehardeshir assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT alimoghaddamkamran assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT vaezimohammad assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT kamranzadehfumanihosein assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT babakhanidavoud assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran
AT tavakolisahar assessingtheprognosticfactorssurvivalandrecurrenceincidenceoftriplenegativebreastcancerpatientsasinglecenterstudyiniran